KY · State regulatory reference

Kentucky.

Moderate

Kentucky's Board of Pharmacy treats compounded semaglutide and tirzepatide (now off the FDA shortage list) as generally impermissible 'essentially copies' except in narrow patient-specific circumstances, per its 2025 GLP-1 guidance and a November 14, 2025 compliance alert, enforceable under 201 KAR 2:076 (which adopted the 2022 USP 795/797/800 revisions, full enforcement from January 1, 2026). As with New Jersey and Oregon, this guidance restates federal 503A rather than a distinctive state rule, and no documented board enforcement order against a specific peptide/GLP-1 compounder was found. Telehealth is permitted with informed consent under KRS 311.5975 and 900 KAR 12:005. (A broader pharmacy-safety bill, HB 729, stalled in committee in the 2026 session.)

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Kentucky Medical Board

https://kbml.ky.gov/ ↗

Pharmacy board

Kentucky Board of Pharmacy

https://pharmacy.ky.gov/ ↗

TPC notes

Telehealth

KRS 311.5975 and 900 KAR 12:005 permit establishing the physician-patient relationship and prescribing via synchronous telehealth with informed consent; Board prescribing standards bar questionnaire-only or telephonic-only initial evaluations, requiring a genuine clinical evaluation.

Compounding

201 KAR 2:076 adopts USP 795/797/800 (2022 revisions, full enforcement from January 1, 2026); Board guidance and the Nov. 14, 2025 alert treat compounded semaglutide/tirzepatide as generally impermissible essentially-copies absent a documented patient-specific clinical difference, echoing federal 503A.

Sources